Forest Laboratories Inc., of New York, and Gedeon Richter plc, of Budapest, Hungary, said Forest submitted a new drug application for cariprazine, a dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors, for use in schizophrenia and bipolar mania
Ranbaxy Laboratories Inc., of Gurgaon, India, launched Absorica (isotretinoin) capsules for severe, recalcitrant, nodular acne in patients younger than 12
BioWorld International | Wednesday, November 28, 2012
Unigene Laboratories Inc., of Boonton, N.J., and Tarix Pharmaceuticals Ltd., of Cambridge, Mass., agreed to develop oral TXA127, Tarix's lead peptide drug candidate
Ranbaxy Laboratories Inc., of Gurgaon, India, launched Absorica (isotretinoin) capsules for severe, recalcitrant, nodular acne in patients younger than 12
Total Value in 2012: $22,056.8M* Number of Deals in 2012:220 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date SEPTEMBER Biogen Idec Inc. (Weston, Mass.) DRI Capital (Toronto) $18.3 Sale of royalty and other undisclosed rights to Benlysta to a fund managed by DRI Capital The royalties stem from a license agreement with Human Genome Sciences Inc., now a unit of GlaxoSmithKline plc, and Glaxo Group Ltd.; the initial payment of $18.3M covered the royalty period
Laboratories Inc. (New York) moksha8 (San Paolo, Brazil) $125 Commercial deal for Latin America giving moksha8 access to Viibryd (vilazodone) Terms call for Forest to provide up to $125M in financing to moksha8 in several tranches over a two-year period 10/24/12 Janssen Biotech Inc. (Horsham, Pa.) Astellas Pharma Inc. (Tokyo) ND Worldwide development and commercialization deal, except for Japan, of ASP015K, an oral, small-molecule Janus kinase inhibitor in Phase IIb development for rheumatoid
Forest Laboratories Inc., of New York, and Adamas Pharmaceuticals Inc., of Emeryville, Calif., partnered to develop a fixed-dose combination (FDC) of Namenda XR (memantine HCl extended release), which is FDA-approved for Alzheimer's, and donepezil HCl for dementia of Alzheimer's in the U.S. The two companies will collaborate on development of the product, with Forest owning exclusive U.S
Valeant Pharmaceuticals International Inc., of Montreal, submitted a citizens petition to the FDA in connection with the agency's determination that Budeprion XL 300 mg, manufactured by Impax Laboratories Inc., and marketed by Teva Pharmaceuticals USA, a part of Teva Pharmaceutical Industries Ltd., of Jerusalem, is not therapeutically equivalent to Wellbutrin XL 300 mg, to request that actions be taken
IGI Laboratories Inc., of Buena, N.J., will launch its first generic products later in 2012, after being appointed the authorized generic distributor for certain products of Medimetriks Pharmaceuticals Inc
Columbia Laboratories Inc., of Livingston, N.J., confirmed that the FDA denied partner Parsippany, N.J.-based Watson Pharmaceuticals Inc.'s formal dispute resolution request (FDRR) related to the new drug application (NDA) for Prochieve (progesterone gel 8 percent) for the prevention of preterm birth in women with a short cervical length
Columbia Laboratories Inc., of Livingston, N.J., said it received a letter from Nasdaq indicating it no longer meets the $1 minimum bid price requirement for continued listing
Discovery Laboratories Inc., of Warrington, Pa., provided a commercial update for Surfaxin (lucinactant) to prevent respiratory distress syndrome in infants and Afectair, an aerosol delivery device
Forest Laboratories Inc., of New York, said it inked a deal with moksha8, of Sao Paolo, Brazil, providing Forest with a commercial footprint in Latin America and giving moksha8 access to antidepressant drug Viibryd (vilazodone) and potentially other Forest products for the Latin American market
Unigene Laboratories Inc